Discovery of novel treatment for intractable vasculitis

发现顽固性血管炎的新疗法

• 批准号: 20590844
• 负责人: TAKAGI Gen
• 金额: $ 2.83万
• 依托单位: Nippon Medical School
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20590844/
• 关键词: 移植・再生医療; 膠原病; ドラッグデリバリー; 血管炎; 血管新生

To date, clinical studies on promoting therapeutic angiogenesis in ischemic tissues have focused exclusively on the use of cell therapy or angiogenic growth factors. In fact, autologous mononuclear cell is reported that potential effective approach for peripheral artery disease and the mechanism is based on the production of variable cytokines from mononuclear cells. An optimal delivery strategy has not been established yet. To establish therapeutic angiogenesis strategies applying for intractable vasculitis, we investigated a therapeutic angiogenesis that could safely cure intractable ulcers, utilizing basic fibroblast growth factor application with a drug-delivery system(DDS). 1^<st> year, we reported ideal methodological approach to evaluate clinical angiogenesis. 2^<nd> to 3^<rd> year, the clinical effect for Churg-Strauss syndrome and SLE were reported. At final year, the effect of this therapy was compared with bone marrow mononuclear cells implantation for atherosclerosis obliterans and Buerger's disease. These widely effective clinical effects for variable intractable vasculitis were published to the book "Vasculitis", with attract attention from worldwide.

到目前为止，促进缺血组织治疗性血管生成的临床研究仅集中在细胞疗法或血管生成生长因子的使用上。事实上，自体单个核细胞被报道为治疗外周动脉疾病的潜在有效方法，其机制是基于单个核细胞产生可变的细胞因子。最优的交付策略尚未确定。为了建立应用于顽固性血管炎的治疗性血管生成策略，我们研究了一种可以安全治愈顽固性溃疡的治疗性血管生成，利用碱性成纤维细胞生长因子与药物输送系统(DDS)相结合的应用。年，我们报道了评估临床血管生成的理想方法学方法。对Churg-Strauss综合征和系统性红斑狼疮的临床疗效进行了报道。在最后一年，将该疗法与骨髓单个核细胞移植治疗动脉粥样硬化闭塞症和Buerger病的效果进行了比较。这些治疗变异性顽固性血管炎的广泛有效的临床效果被发表在《血管炎》一书中，引起了全世界的关注。

项目成果

【患者までとどいている再生誘導治療バイオマテリアル生体シグナル因子、細胞を利用した患者のための再生医療の実際】組み合わせ足場と細胞増殖因子皮膚真皮皮膚真皮の再生誘導治療.

[使用生物材料生物信号因子和细胞的患者实际再生医学] 使用组合支架和细胞生长因子对患者进行再生诱导治疗。

• 发表时间: 2009
• 期刊: 遺伝子医学MOOK
• 作者: 宮本正章;高木元;太良修平;水野博司;田畑泰彦;水野杏一
• 通讯作者: 水野杏一

皮膚組織の再生医療

皮肤组织再生医学

• 发表时间: 2008
• 期刊: Medical Science Digest
• 作者: 宮本正章;高木元;高野仁司;川中秀和;大坪春美;水野博司;田畑泰彦;水野杏一
• 通讯作者: 水野杏一

Total Managemof Ischemic Wound in an Era of TherapeutiAngiogenesis

血管生成治疗时代的缺血性伤口的全面管理

• 发表时间: 2011
• 作者: Gen Takagi;Masaaki Miyamoto;Shuhei Tara;Ikuyo Takagi;Hitoshi Takano;Masahiro Yasutake;Yasuhiko Tabata;Kyoichi Mizuno
• 通讯作者: Kyoichi Mizuno

EnhancedVascularization by Controlled Release of Platelet-Rich Plasma impregnated in gelatin hydrogels for Critical Limb Ischemia in Rats

通过控制释放富含血小板的血浆浸渍在明胶水凝胶中来增强血管化，治疗大鼠严重肢体缺血

• 发表时间: 2010
• 作者: Jiro Kurita;Masaaki Miyamoto;Yosuke Ishii;Gen Takagi;Shuhei Tara;Kyoichi Mizuno;Yoshimitsu Fukushima;Shin-ichiro Kumita;Zenya Naito;Yasuhiko Tabata;Masami Ochi;Kazuo Shimizu
• 通讯作者: Kazuo Shimizu

Long-term Clinical Outcome Cost Effectiveness of Autologous Bone Marrow Mononuclear Cell Implantation in Patients with Critical Limb Ischemia

自体骨髓单核细胞移植治疗严重肢体缺血患者的长期临床结果成本效益

• 发表时间: 2010
• 作者: Hitoshi Takano;Masaaki Miyamoto;ShuTara;Gen Takagi;Koji Katoh;SonokoKirinoki;Masahiro Yasutake;Kyoichi Mizuno
• 通讯作者: Kyoichi Mizuno